secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001437749-26-012879
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex inks new MD Anderson SRA for Reqorsa biomarkers; trial updates show partial responses
--------------------------------------------------------------------------------

- New Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN as biomarkers for Reqorsa in NSCLC and SCLC.
- Acclaim-1 Phase 2a enrolling; Phase 1 showed no DLTs, one patient had partial remission for ~42 months (60 courses) on Reqorsa+Tagrisso.
- Acclaim-3 Phase 2 enrolling; Phase 1 showed no DLTs, one patient had unconfirmed partial remission after 24 cycles (>18 months) on Reqorsa+Tecentriq.
- Both trials combine Reqorsa (quaratusugene ozeplasmid) with approved targeted therapies; early signs of efficacy reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926012879/0001437749-26-012879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926012879/gnpx20260329_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-012879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer